Comparative Pharmacology
Head-to-head clinical analysis: AZOLID versus COXANTO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AZOLID versus COXANTO.
AZOLID vs COXANTO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), specifically interfering with peptidoglycan cross-linking.
Selective inhibitor of soluble epoxide hydrolase (sEH), increasing levels of epoxyeicosatrienoic acids (EETs), which have vasodilatory, anti-inflammatory, and antifibrotic effects.
2 g intravenously every 6-8 hours; maximum 8 g/day.
1 g intravenous every 6 hours.
None Documented
None Documented
Terminal half-life 1.5-2 hours in normal renal function; prolonged to 4-8 hours in severe renal impairment (CrCl <30 mL/min)
Clinical Note
moderateFurazolidone + Torasemide
"Furazolidone may increase the hypotensive activities of Torasemide."
Clinical Note
moderateFurazolidone + Travoprost
"Furazolidone may increase the hypotensive activities of Travoprost."
Clinical Note
moderateFurazolidone + Unoprostone
"Furazolidone may increase the hypotensive activities of Unoprostone."
Clinical Note
moderateFurazolidone + Hydrochlorothiazide
"Furazolidone may increase the hypotensive activities of Hydrochlorothiazide."
Terminal elimination half-life: 12-15 hours (prolonged to 24-30 hours in moderate-to-severe renal impairment, requiring dose adjustment)
Renal (80-90% unchanged), biliary/fecal (10-20%)
Renal: 70% unchanged; biliary/fecal: 20% as metabolites; 10% other
Category C
Category C
NSAID
NSAID